Nearly a decade after spinning out its Chinese research hub to form Dizal Pharmaceutical, AstraZeneca is
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
AstraZeneca licenses worldwide rights to Dizal's lung cancer pill Zegfrovy for $600M upfront, plus up to $900M in milestones and…
Antibody-drug conjugates from Kelun-Biotech and Hansoh Pharma, respectively partnered with Merck & Co. and GSK, delivered…
Editor's Note: The story will be updated after the study's presentation Friday afternoon. Please check back later. | About three…
AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday
In the wake of a recent safety scare in a confirmatory trial of its antibody-drug conjugate Zynlonta, ADC Therapeutics is…
After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor (ASI)…
